Wedbush Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $30

Benzinga Newsdesk www.benzinga.com Negative 93.5%

Neg 93.5% Neu 0% Pos 0%

Wedbush analyst Robert Driscoll maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and lowers the price target from $38 to $30.